| Description | Niceritrol (Cardiolipol) is a niacin ester that reduces cholesterol and triglycerides in total plasma and in the VLD and LD lipoprotein fractions. |
| Synonyms | Perycit, Cardiolipol, 戊四烟酯, Bufor |
| molecular weight | 556.52 |
| Molecular formula | C29H24N4O8 |
| CAS | 5868-05-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 12 mg/ml (21.56 mM) |
| References | 1. Owada A, Suda S, Hata T. Antiproteinuric effect of niceritrol, a nicotinic acid derivative, in chronic renal disease with hyperlipidemia: a randomized trial. Am J Med. 2003 Apr 1;114(5):347-53. 2. Yamamoto K, Fukushima N, Ozaki I, Setoguchi Y, Yanagita T, Sakai T. New combined therapy of niceritrol and probucol on heterozygous familial hypercholesterolemia. Artery. 1991;18(3):133-49. 3. Kuboyama N, Watanabe Y, Yamaguchi M, Sato K, Suzuki T, Akiba T. Effects of niceritrol on faecal and urinary phosphate excretion in normal rats. Nephrol Dial Transplant. 1999 Mar;14(3):610-4. 4. Nagakawa Y, Orimo H, Harasawa M. The anti-platelet effect of niceritrol in patients with arteriosclerosis and the relationship of the lipid-lowering effect to the anti-platelet effect. Thromb Res. 1985 Nov 15;40(4):543-53. |